A composition for increasing sexual pleasure in an adult human includes: a dosage form selected from capsules, tablets, oral drops, infused edibles, infused food preparations, infused drink preparations, massage oils, lotions, gels, creams, lubricants, patches, and suppositories, the dosage form containing: a quantity of a PDE5 inhibitor that is no greater than 50% of a full prescription quantity or dose of the PDE5 inhibitor for an adult male; and a quantity of a cannabinoid component sufficient to amplify the effect of the PDE5 inhibitor to at least 80% of the effect of the full prescription quantity or dose for an adult male, wherein the PDE5 inhibitor and the cannabinoid component are effective in increasing sexual pleasure in the adult human in need thereof, including at least one of increased blood flow to erectile tissue, increased sexual desire, increased sexual arousal, increased sexual sensitivity, or increased strength of orgasm.
A composition for increasing sexual pleasure in an adult human includes:
a dosage form selected from capsules, tablets, oral drops, infused edibles, infused food preparations, infused drink preparations, massage oils, lotions, gels, creams, lubricants, patches, and suppositories, the dosage form containing:
a quantity of a PDE5 inhibitor that is no greater than 50% of a full prescription quantity or dose of the PDE5 inhibitor for an adult male; and
a quantity of a cannabinoid component sufficient to amplify the effect of the PDE5 inhibitor to at least 80% of the effect of the full prescription quantity or dose for an adult male,
wherein the PDE5 inhibitor and the cannabinoid component are effective in increasing sexual pleasure in the adult human in need thereof, including at least one of increased blood flow to erectile tissue, increased sexual desire, increased sexual arousal, increased sexual sensitivity, or increased strength of orgasm.
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 36/16 - Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
A61K 36/21 - Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
Composition for the treatment of sexual dysfunction, low sexual desire, arousal disorder, and orgasmic disorder in a male or female. The composition includes (i) a therapeutically effective amount of a sexual pleasure enhancing component comprising at least 5 mg of tetrahydrocannabinol (THC) to enhance sexual sensitivity and pleasure and (ii) at least 500 mg, 1 gram, or 2 grams of a sexual response component comprising at least 500 mg by combined weight of a plurality of supplements selected from the group consisting of L-arginine, L-citrulline, yahimbe root, ginseng (e.g., Korean red ginsing), ginkgo biloba, horny goat weed, goosefoot, Chenopodium ambrosioides, Chlorophytum borivilianum, Desmodium gangeticum, garlic combined with vitamin C, damiana, and herbal supplements that increase blood flow to the genital region and are not cannabinoids. The sexual pleasure enhancing component and the sexual response component synergistically increase sexual pleasure in the human in need thereof, strength of orgam.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 9/00 - Medicinal preparations characterised by special physical form
Composition for the treatment of sexual dysfunction, such as erectile dysfunction, low sexual desire, arousal disorder, and orgasmic disorder in a male or female. The composition includes (i) a therapeutically effective amount of a cannabinoid component that enhances sexual sensitivity and pleasure including at least one of tetrahydrocannabinol and cannabidiol and (ii) a therapeutically effective amount of a sexual response component that increase blood flow to the genital region selected from sildenafil, tadalafil, vardenafil, L-arginine, yohimbe, ginseng, Gingko biloba, horny goat weed, and herbal supplements that increase blood flow to the genital region. The amounts and/or ratio of THC and CBD can be selected depending on age, gender, physical health, and/or psychological condition of the user. The cannabinoid component and the sexual response component interact synergistically to treat various types of human sexual dysfunction.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
Cannabis, and cannabidiol (CBD), which is less or non-psychoactive and modulates THC activity. The ratio of THC/CBD can be selected depending on age, gender, physical health, and/or psychological condition of the user.
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
Pharmaceutical preparations include at least one component that enhances sexual response and at least one other compound that enhances sexual sensitivity and pleasure. The component that enhances sexual response (e.g., PDE5 inhibitor) enhances blood flow to the genital region. Examples include compounds that dilate blood vessels, such as compounds that increase the amount of nitric oxide (NO) in the blood. The component that enhances sexual sensitivity and pleasure includes one or more cannabinoid compounds from the plant genus Cannabis, including extracted compounds, synthetic forms, and derivatives thereof. Examples include tetrahydrocannabinol (THC), the main psychoactive constituent of Cannabis, and cannabidiol (CBD), which is less or non-psychoactive and modulates THC activity. The ratio of THC/CBD can be selected depending on age, gender, physical health, and/or psychological condition of the user.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
Cannabis, and cannabidiol (CBD), which is less or non-psychoactive and modulates THC activity. The ratio of THC/CBD can be selected depending on age, gender, physical health, and/or psychological condition of the user.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A23L 29/30 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing carbohydrate syrupsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugarsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugar alcohols, e.g. xylitolFoods or foodstuffs containing additivesPreparation or treatment thereof containing starch hydrolysates, e.g. dextrin
8.
Method of improving sexual response and sensitivity
Cannabis, and cannabidiol (CBD), which is less or non-psychoactive and modulates THC activity. The ratio of THC/CBD can be selected depending on age, gender, physical health, and/or psychological condition of the user.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A23L 27/20 - Synthetic spices, flavouring agents or condiments
A21D 13/40 - Products characterised by the type, form or use
Cannabis, and cannabidiol (CBD), which is less or non-psychoactive and modulates THC activity. The ratio of THC/CBD can be selected depending on age, gender, physical health, and/or psychological condition of the user.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
patents
